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Abstract: Osteoarthritis (OA) is the most common degenerative joint disorder worldwide and to
date no regenerative treatment has been established in clinical practice. This review evaluates the
current literature on the clinical translation of mesenchymal stromal cell (MSC)-based therapy in OA
management with a focus on safety, outcomes and procedural specifics. PubMed, Cochrane Library
and clinicaltrials.gov were searched for clinical studies using MSCs for OA treatment. 290 articles were
initially identified and 42 articles of interest, including a total of 1325 patients, remained for further
examination. Most of the included studies used adipose tissue-derived MSCs or bone-marrow-derived
MSCs to treat patients suffering from knee OA. MSC-based therapy for knee OA appears to be safe
and presumably effective in selected parameters. Yet, a direct comparison between studies was
difficult due to a pronounced variance regarding methodology, assessed outcomes and evidence
levels. Intensive scientific engagement is needed to identify the most effective source and dosage of
MSCs for OA treatment in the future. Consent on outcome measures has to be reached and eventually
patient sub-populations need to be identified that will profit most from MSC-based treatment for OA.




With a steadily increasing prevalence in past decades, 14 million US individuals are currently
estimated to suffer from symptomatic knee OA [1]. A constantly aging society will lead to a dramatic
rise in affected patients and concomitant joint replacement surgery in the coming years [2].
Underlying pathomechanisms of OA are versatile and include both, intrinsic and extrinsic factors.
Intrinsic factors include age, gender, menopause, genetics, nutrition and bone density, and extrinsic
or mechanical factors include body weight, body mass index (BMI), injuries, previous surgeries and
joint deformities, which are all directly linked to an increased susceptibility to OA [3,4]. Mostly a
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combination of these factors and very seldom a single factor alone, leads to a chronic low-grade joint
inflammation and a progressive loss of cartilage. Symptoms consist of stern long-term pain, physical
disability and a decrease in quality of life [5]. Interestingly, idiopathic OA, unrelated to a specific
evident cause or underlying disease, contributes to a high number of OA cases [6].
Self-healing potential in OA is low, which is partly due to the absence of blood vessels and the
low metabolic activity of chondrocytes in joint cartilage. Existing treatment strategies for OA generally
start with a conservative approach, including physical therapy, exercise and activity modification
as well as prescription of analgesics. Non-steroidal anti-inflammatory drugs (NSAIDs) aim at
reducing pain and inflammation in the joint. In addition, intra-articular hyaluronic acid (HA)-,
glucocorticoid (GC)- or platelet-rich plasma (PRP)-injections are used to achieve temporary analgesia
and to reduce inflammation [7]. Continuously progressing OA, which cannot be sufficiently controlled
by conservative treatment, can currently only be treated by a few joint-preserving surgical interventions
(e.g., osteotomy, joint distraction). Conservative treatment and joint preserving surgery aim at pain
reduction and symptom control to prolong the time to unilateral or ultimately total joint replacement
surgery, which can effectively replace but not restore joint integrity.
Data from the Norwegian Arthroplasty Register show the ten-year survival rate of primary total
knee arthroplasties to be between 89.5% and 95.3% [8]. Further data analyses from the same registry
found the ten-year survival rate of primary total knee arthroplasties to be 92.5% in low volume hospitals
and 95.5% in high volume hospitals [9]. Despite high overall prosthesis survival rates, implant survival
is still highly dependent on the age of patients. Limited prosthesis durability poses still a problem for
younger patients and those with impaired bone quality, resulting in increased risks of periprosthetic
joint infection, aseptic mechanical failure and subsequent revision surgery [10,11].
Disease modification, potential cartilage repair and regeneration have long been missing in the
range of therapeutic options for OA patients. However, the preclinical work has come to a point
where cellular therapies to target OA, have become feasible and applicable in first clinical trials over
the past decade. A number of clinical trials have recently been performed, that paved the way for a
greater acceptance of regenerative cell therapies in OA treatment regimens [12]. Despite a number
of unknowns, cell-based treatment created great hopes in OA-affected patients and has become the
“poster child” of regenerative medicine.
1.2. Mechanisms of Action behind MSCs
Dedicated efforts to decipher and explain regenerative properties and mechanisms of action
behind MSCs are part of past and current pre-clinical and clinical studies. Different paradigms and
theories have evolved over the years, resulting in two suspected major mechanisms of action on how
MSCs could exert their regenerative abilities in OA:
(1) The initially favoured theory, that MSCs mainly differentiate into cells of a specific mesodermal
lineage and replace damaged or missing cells has lost its popularity in recent years. However,
MSCs seem to share the ability to induce tissue regeneration through the stimulation of local
endogenous cells [13].
(2) Today, the major potential of MSCs is seen in their secretion of paracrine factors (“bystander effect”),
that allows an immunomodulation of the local pro-inflammatory environment, which plays a key
role in cartilage degeneration in OA [14,15]. Whether paracrine effects are long-lasting or merely
a “hit and run” phenomenon is currently debated [16].
1.3. First MSC Trials and Cartilage Repair
The origin of today’s cell-based therapy concepts dates back to the 1960s, when Friedenstein
characterized mesenchymal stem cells or MSCs [17]. MSCs are multipotent precursor cells of
mesodermal origin. They are able to differentiate into tissue cells of the mesodermal lineage like
chondrocytes, osteoblasts, adipocytes and myocytes. Even a differentiation into neuronal cell types has
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been described [18]. Due to their differentiation potential, MSCs raised the hope to be exploitable in
the treatment of degenerative diseases such as OA through the regeneration of damaged cartilage.
Ashton et al. were the first to report of the chondrogenic potential of MSCs in vivo in 1980 [19].
30 years later, Mokbel et al. showed that the repair of damaged articular cartilage tissue happened
through homing, engraftment and production of cartilage matrix by MSCs [20]. Further animal
experiments using MSCs for the treatment of OA followed, demonstrating reduced articular cartilage
degeneration, osteophytic remodelling, and subchondral sclerosis after intra-articular injection of
MSCs [13,21,22].
Early in vitro studies demonstrated the capacity of MSCs to form cartilage-like tissue, evident by
the production of type II collagen and hypertrophic chondrocytes after growth-factor stimulation [23].
Yet, the quality of tissue-engineered cartilage was reported to be compromised, indicated by low
collagen contents with a presumably negative impact on the load-carrying properties of cartilage [24].
New cell-carrier scaffolds, made from natural cartilage extra-cellular matrix, promoted proliferation and
chondrogenic differentiation of bone-marrow-derived MSCs (BMMSCs) without outside stimulations
in an in vivo animal model [25].
A 2002 study published by Wakitani et al. marked one of the first OA trials of BMMSCs used in
humans. Twenty four patients suffering from knee OA were either treated with a high tibial osteotomy
(HTO) combined with intra-articular autologous cultured BMMSC injections or with an HTO alone as a
control group. At the 16-month follow-up, pain scores, function and muscle strength had significantly
improved in the treatment compared to the control group [26].
With the rise of this new cellular-based therapy, concerns about the quality of autologous MSCs
from patients suffering from OA arose. In 2002 Murphy et al. described a compromised ability
of MSCs from OA patients to differentiate into chondrocytes [27]. A more recent study however
found that MSCs from OA patients did in fact have the same chondrogenic differentiation potential
as age-matched patients with femoral fractures [28]. These contradicting results may be explained
by the fact that the compared patient collectives in the study by Murphy et al. [27] were not strictly
age-matched and an isolated impact of age may not be disregarded, as MSCs were described to lose
their chondrogenic differentiation potential with age [29–31]. The authors further discussed whether
the reduced differentiation potential of progenitor cells may even be a cause for OA, rather than a
result of it [27].
An increased chondrocyte proliferation was observed when chondrocytes were co-cultured with
MSCs and proliferation was further associated with the ability to synthesize cartilaginous extracellular
matrix in vitro [32,33]. In turn, anti-proliferative effects have been described, when MSCs were
challenged with “negative” signals, like interferon-γ or bacterial stimuli like lipopolysaccharide [22,34].
1.4. OA as an Inflammatory Disease and Immunomodulatory Properties of MSCs
For a long time, OA was classified as a non-inflammatory “wear and tear” disease. This changed
through the works of Goldring and Scanzello et al., who helped to categorize OA as a stress-induced
and pro-inflammatory disease in 2011 [35,36].
Numerous studies followed, concluding the same and showing a direct role of pro-inflammatory
factors, such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β in OA pathogenesis [37,38].
Since then inflammation and synovitis have been fundamentally included in the theoretical framework
of the OA pathomechanism and are also considered targets for new treatment modalities such
as MSC-based therapy [16,39]. In addition to the differentiation potential of MSCs towards
chondrocytes and the recruitment of neighbouring progenitor cells, it was proven that MSCs have
potent anti-inflammatory as well as immunomodulatory properties [40,41].
Immunomodulatory effects of MSCs were reported for adipose tissue-derived MSCs (ATMSCs)
from different adipose tissues (abdominal fat, infrapatellar Hoffa fad pad, subcutaneous hip
fat), as they show a reduction of inflammatory factors like TNF-α, IL-1β and CCL3/macrophage
inflammatory protein-α, when co-cultured with chondrocytes and synoviocytes from OA patients [42].
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The immunomodulatory effects of ATMSCs and BMMSCs show some similarities, as both cell types
reduce T-cell numbers and subsequent pro-inflammatory cytokines [43,44].
The mechanism behind the regulation of local inflammatory environments, is in part explained by
the secretion of growth factors, chemokines, cytokines, micro-RNAs and extracellular vesicles (EVs) by
MSCs. MSC-secreted factors affect macrophages, dendritic cells, T- and B-cells, neutrophils and natural
killer cells [45]. Further, ATMSCs and BMMSCs decrease antibody production and B-cell chemotaxis
by inhibition of B-cell proliferation through cell-cycle arrests and apoptosis in a T-cell independent
manner [46,47].
Keeping in mind that inflammation plays a key role in osteoarthritic joints, immunomodulatory
properties have been used to explain partial joint tissue healing through MSCs. The deployment of
a suitable environment for tissue regeneration by MSCs may therefore either be achieved by direct
secretion of bioactive materials or by controlling and containing cytokine and growth factor production
from effector cells [44]. Anti-inflammatory and immunomodulatory effects of MSCs can further be
modulated and enhanced by ex vivo “priming” of MSCs with cytokines, hypoxia, chemical agents,
biomaterials, and receptor challenging. A comprehensive literature overview regarding priming
approaches for MSCs was recently published by Noronha NC et al. [48] and a summary of growth
factors, chemokines, cytokines, micro-RNAs and EVs, secreted by MSCs was provided by Lin et al. [45].
1.5. Oncological Safety Profile of MSCs
Due to the high proliferative capacities of MSCs and the potential of tumour-derived cytokines
to attract MSCs to tumour sites, oncological side effects must be discussed when assessing the safety
profiles of cell-based therapies. MSCs have shown to exert potential tumorigenicity in several murine
and in vitro models, yet no novel cancers or cancer recurrences have been diagnosed in clinical trials to
date, that would originate from administered MSCs as summarized in recent reviews by Lee et al. [49]
and Ridge et al. [50].
Toyserkani et al. conducted a concise systematic review about the safety of ATMSCs in
2017, assessing 70 studies with over 1400 patients, who received ATMSCs for various conditions.
Thromboembolic complications were registered for the systemic application of MSCs, yet the local
treatment appeared to be safe, especially regarding oncological side effects. One case of breast cancer
recurrence was identified in 121 patients with a known history of previous breast cancer. Although the
authors came to the conclusion that ATMSCs have a favourable oncological safety profile, they stressed
the low quality of reporting of adverse events (AEs) and the short follow-up period of 12 months [51].
Standardized reporting systems for AEs and long-term follow-ups of several years are therefore needed
to fully evaluate the oncological safety of MSC-based therapy in the future.
1.6. Preparation of MSCs
MSCs can be harvested from various tissues of mesenchymal origin. These include e.g., bone-marrow,
adipose tissue, synovial fluid, skeletal muscle and the placenta. MSC-based therapy for OA follows
the basic principle of a local application of harvested cells into the affected joint, after ex vivo isolation,
concentration or cell expansion. Delivery of MSCs is either achieved through an intra-articular injection
or an arthroscopically assisted implantation of MSCs. The distinction between autologous and allogenic
sources stems from the origin of MSCs. Allogenic cells are harvested from a suitable donor, whereas
autologous cells originate from the patients themselves. In general, autologous MSCs are often seen
as the safe choice, as concerns about unwanted immune-responses or transplant rejections can be
disregarded [52]. The complex autologous MSC preparation procedure that may include cell culture
and expansion, makes autologous solutions however a more complicated and expensive method
opposed to allogenic alternatives. Allogenic MSCs are cheaper and logistically more convenient,
as they can be obtained as an off-the-shelf product [53].
In the context of ex vivo expansion, xenogenic elements (e.g., remains of fetal bovine serum)
should, if possible, be replaced by humanized material or eliminated as far as possible to reduce
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post-transplantation risks such as transmission of microbes (viruses, bacteria, prions), cytotoxicity,
uncontrolled and unpredictable growth patterns as well as the theoretical risk of anaphylactic
reactions [54].
Further, some patients’ comorbidities (e.g., anaemia, severe osteoporosis) do not allow harvesting
of autologous MSCs and certain underlying autoimmune conditions like rheumatoid arthritis [55,56]
and type 2 diabetes [57], may impair the immunosuppressive capacities of MSCs, which in those cases
leaves allogenic MSC-based therapies as the more feasible choice. Generally, three types of altered
autologous MSC products can be distinguished:
(1) MSC concentrates are the product of harvested fluids or tissues, which have been concentrated
in order to increase the number of MSCs per unit of applied suspension. Bone-marrow
aspirate concentrates (BMAC) include high concentrations of growth factors and high levels of
anti-inflammatory IL-1 receptor antagonist next to MSCs [58].
(2) Culture-expanded MSCs can be administered without scaffolds or seeded onto scaffolds after
having been isolated and cultured. Traditionally two-dimensional (2-D) plastic culture plates
are in use for cell expansion, but three-dimensional (3-D) techniques have evolved in recent
years. 3-D cultures are able to mimic in vivo conditions and provide high density and expansion
potential [59]. New additions like highly elastic culture dishes, automatically adapting the dishes’
surface to growing cell numbers, optimize the expansion process before MSCs are ready for
application [60]. Increased complexity and non-standardized expansion protocols, alongside
higher costs should be taken into consideration, when applying 3-D expansion techniques.
However, reports about increased immunomodulatory and chondrogenic potential of MSCs,
cultured in 3-D compared to conventional 2-D cultures, point towards promising technical
developments in the field of tissue engineering for OA treatment [61,62].
(3) The stromal vascular fraction (SVF) is a combination of ATMSCs, endothelial cells, growth factors,
precursor cells, macrophages, t-regulatory cells, lymphocytes and others. The SVF is derived
from lipoaspirates by mechanical or enzymatic isolation [63]. The SVF can be injected into the
joint, after a purification process, often within the same visit, as there is no need for expansion or
culturing of cells.
As with many novel therapeutic strategies, a standard is not yet available and different approaches
are present in the current literature regarding cell origin, harvesting technique, cell dose, culturing and
application. Moreover, controversy prevails regarding outcome measurements and follow-up times
in current study designs. In this review we analysed the relevant clinical literature on MSC-based
treatment for OA with special regards to safety and efficacy. As the field of regenerative medicine and
especially the use of MSCs in degenerative joint disorders has become more and more relevant for
the medical and public community, we hope to shed some light on this valuable and fast-evolving
treatment concept.
2. Methods
First step: A literature search was performed to identify all relevant articles, involving MSC-based
treatment for OA. Pubmed (MEDLINE), The Cochrane Library and clincialtrials.gov were searched
until the 13 of April 2020. For Pubmed and The Cochrane Library searches, MeSH (Medical Subject
Headings)-terms were used as shown below.
(1) PubMed MeSH search terms: “mesenchymal stem cell transplantation” [Mesh] AND “osteoarthritis”
[Mesh]: 290 results
(2) Cochrane Library MeSH search terms: #1 MeSH (“mesenchymal stem cell transplantation”)
explode all trees AND #2 MeSH (“osteoarthritis”) explode all trees: 16 results
(3) ClinicalTrials.gov search terms: “mesenchymal stem cells” OR “mesenchymal stromal cells” AND
“osteoarthritis”: 96 results
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Second step: Relevant studies were identified through abstract information and then included or
excluded after full-text evaluation.
We included all clinical studies, that used MSCs to treat OA in humans, with a recruitment of
at least seven participants. Articles from any country were included but limited to those published
in English language. We excluded any preclinical studies, case reports, review articles and studies
addressing isolated, focal chondral defects not clearly associated with OA. Further excluded were all
articles older than ten years, to ensure actuality of this review.
Third step: Reference lists of included articles were scanned regarding potentially missed studies.
Missed studies were then identified and added by hand.
Fourth step: Included articles were analysed regarding number of patients, follow-ups, treatment
details, outcome measures, study type, control arm and site of OA (see Table 1).
The initial literature search of PubMed yielded a total of 290 articles. The search of The Cochrane
Library database yielded 16 results, of which all had already been covered by the previous Pubmed
search. After removal of duplicates 290 articles were scanned and full-text evaluation followed.
34 articles were identified as relevant to this review. The reference lists of the 34 selected articles
were scanned regarding missed studies and eight studies were added by hand. A total of 42 studies,
including 1325 patients, were examined in detail (see Figure 1 and Table 2).
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Table 1. Studies “currently recruiting” patients for MSC-based therapies for OA, listed on clinicaltrials.gov, categorized by study design and sorted by number
of patients.
Indication Number of Patients Source of MSCs Intervention Control Study Phase Location and Study Identifier
Double-blinded randomized controlled trials





Jinju-si, Seoul, all: Republic of
Korea (South)
(NCT03990805)
Knee OA 153 Autologous ATMSCs Single intra-articular injection of ATMSCs (1 or2 × 107 cells) vs. control Saline II
Montpellier, France
(NCT02838069)
Knee OA 60 Allogenic UCMSCs Single intra-articular injection of allogenic UCMSCs(107 cells) + PRP (5 mL) vs. control HA I/II
Liaocheng, Shandong, China
(NCT03166865)
Knee OA 60 Autologous BMMSCs
Repeated (three) intra-articular injections of
autologous BMMSCs
+ PRP (3 mL) vs. control over six months
PRP II Yantai, Shandong, China(NCT03969680)
Knee OA 40 Autologous ATMSCs Single intra-articular injection of autologous ATMSCsvs. control GC III
Stanford, California, USA
(NCT03467919)












Single intra-articular injection of low dose dental pulp
MSCs vs. high dose dental pulp MSCs vs. control HA I
Shanghai, China
(NCT04130100)
Knee OA 60 Autologous ATMSCs
Repeated (three) intra-articular injections of
autologous ATMSCs + PRP (3 mL) vs. control over
six months
PRP II Yantai, Shandong, China(NCT04212728)
Knee OA 48 Autologous ATMSCs Single intra-articular injection of autologous ATMSCsvs. control GC III
Beirut, Lebanon
(NCT04230902)
Knee OA 30 Allogeneic ATMSCs Single intra-articular injection of allogeneic ATMSCs(6.7 × 106 or 4 × 107) vs. control HA I/II
Hsinchu, Taiwan
(NCT03943576)
Knee OA 30 Autologous ATMSCs HTO followed by intra-articular autologous ATMSCinjection vs. control, one month post osteotomy HA I/II
Jinan, Shandong, China
(NCT03955497)
Knee OA 9 Allogenic UCMSCs
Repeated (three) intra-articular injections of allogenic
UCMSCs (107 cells) + HA (2 mL) + recombinant
human somatropin (8 IU) vs. allogenic UCMSCs +
HA vs. control weekly over three weeks
HA I Jakarta, Indonesia(NCT03800810)
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Table 1. Cont.
Indication Number of Patients Source of MSCs Intervention Control Study Phase Location and Study Identifier
Prospective uncontrolled trials
Knee, hip,
glenohumeral OA 100 Autologous ATMSCs
Repeated (three) intra-articular injections of
autologous ATMSCs every three months over 12
months (≥ 106 cells per injection)
- I/II Warsaw, Poland(NCT03869229)
Knee, hip,
glenohumeral OA 100 Allogenic WJMSCs
Repeated (three) intra-articular injections of allogenic
WJMSCs every three months over 12 months (≥ 106
cells per injection)
- I/II Warsaw, Poland(NCT03866330)
Glenohumeral OA 30 Autologous BMAC Single intra-articular injection of autologous BMAC(9 mL) - -
Rozzano, Milano, Italy
(NCT04308213)
Knee OA 25 Autologous BMAC Single subchondral and intra-articular injection ofautologous BMAC (6 mL) - -
Rozzano, Milano, Italy
(NCT03790189)
Hip OA 24 Autologous ATMSCs
Single intra-articular injection of ATMSCs (3 × 107






Knee OA 24 Allogenic UCMSCs Single intra-articular injection of allogenic UCMSCs(2, 20 or 80 × 106 cells) - I
Santiago, Chile
(NCT03810521)




Knee OA vs. focal
chondral defect of
the knee
16 Autologous BMMSCs Single intra-articular injection of autologousBMMSCs (5 × 107 cells) - I
Cleveland, Ohio, United States
(NCT03477942)
Knee OA 15 Allogenic BMMSCs Single intra-articular injection of allogenic BMMSCs(1, 5 or 10 × 107 cells) - I/IIa
Taipei, Taiwan
(NCT03589287)
Knee OA 12 AllogenicUCMSCs
Single intra-articular injection: low dose vs. mid dose
vs. high dose (4, 10 or 20 × 106 cells / 2 mL) - I
Seoul, Jongno-gu, Republic of
Korea (South)
(NCT04037345)
Knee OA 10 Allogenic WJMSCs Repeated (two) intra-articular injections of allogenicWJMSCs (5 × 107 cells in each dose) - I
Amman, Jordan
(NCT02963727)
Knee OA 10 Autologous ATMSCs Repeated (two) intra-articular injections ofautologous ATMSCs (5 × 107 cells in each dose) - I
Amman, Jordan
(NCT02966951)
Knee OA 8 Autologous ATMSCs Single intra-articular injection of ATMSCs - - Qilu, Shandong, China(NCT03956719)
ATMSC = adipose tissue-derived mesenchymal stromal cell; BMAC = bone-marrow aspirate concentrate; BMMSC = bone-marrow-derived mesenchymal stromal cell; GC = glucocorticoid;
HA = hyaluronic acid; HTO = high tibial osteotomy; MSC = mesenchymal stromal cell; OA = osteoarthritis; PRP = platelet-rich plasma; UCMSC = umbilical cord-derived mesenchymal
stromal cell; WJMSC = Wharton Jelly-derived mesenchymal stromal cell.
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Table 2. Included studies, categorized by tissue origin and sorted by study type, number of patients and follow-up.
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Knee K.L. ≥ 2 30 12 months Double-blinded
Intra-articular
injection of 107 cells
(n = 10) mixed with
1.5 mL of saline vs.




injection of 4 mL of


















- Pain VAS score improved
significantly in low- and
high-dose treatment groups




group compared to baseline




to baseline. X-ray images
revealed joint space
reduction in the control
group but not in the
high-dose treatment group
(assessment in the low-dose
group was not possible).
MRI improvements were
















- No SAEs or AEs.
- At the 4-year follow-up,
significant improvements
in pain VAS and WOMAC
scores were observed for
the low- and high dose







Knee K.L. 2–4 43 Six months Triple-blinded
Intra-articular
injection of 4 × 107
cells in 5 mL of saline
with 2% human
serum albumin












of saline with 2%
human serum
albumin (n = 24)
- No significant AEs.
- Significant improvement
in painless walking
distance and WOMAC pain
sub-scale in the MSC group
compared to placebo over
time.
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Table 2. Cont.




Arms and Mean Cell
Numbers
Outcome





Knee - 56 24 months -
HTO, microfracturing
and intra-articular
injection of 1,46 × 107
cells mixed with 2 mL












injection of 2 mL
of HA (n = 28)
- No treatment-related
SAEs.
- The MSC group showed a
significantly greater added
improvement in all clinical
scores, compared to the
control group at the final
follow-up. MRI showed
significantly better results
compared to the control




















- The MSC group showed a
continuous decline of pain
VAS score and KOOS at
each follow-up compared
to the control group.





Knee - 47 12 months Double-blinded
Intra-articular
injection of MSCs
alone (n = 16) vs.














in all three groups in most
KOOS domains and global
score after one month and
in all KOOS domains and
global score at the
12-month follow-up.
MSC and MSC + PRP
groups showed the highest
percentage of
improvement.









18 12 months Double-blinded
Intra-articular
injection of MSCs +
PRP (n = 9) vs.
injection of MSCs







SAEs (intense knee pain)
and eight treatment-related
AEs that resolved without
any sequelae in five
patients.
- KOOS was significantly
improved in both groups
throughout a follow-up
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Table 2. Cont.




Arms and Mean Cell
Numbers
Outcome







Knee K.L. 1–4 76 13–22months -
Intra-articular
injection of BMAC
(n = 41) vs. micro
fragmented adipose








in KOOS, EQOL, and pain
VAS score for both groups
with no significant
difference between groups.




Knee K.L. ≥ 3 12 24 months Radiologistblinded
Four cohorts; n = 3 in
each of the first three
cohorts received 1, 10
or 50 × 106 cells; in
cohort four n = 3
received either 1, 10








- No SAEs, four patients
with minor transient AEs.




difference (MID) in all
scores except for KOOS (2/4
patients showed
improvements) and quality
of life (3/4) at the 12-month
follow up; two of four
patients in the 1 x 106 group
and one in the 10 × 106
group showed MID in all
scores; the 50 × 106 cohort
had the greatest number of
patients achieving MID










(n = 6), ankle
(n = 6), hip
(n = 5)
K.L. 3/4 17 30 months -
Intra-articular
















in WOMAC score and
walking distance in all
patients. Pain VAS score
improved significantly at




were mainly present in the
first six months (descriptive
only).
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Table 2. Cont.




Arms and Mean Cell
Numbers
Outcome
Measures Study Type Control Arm Main Results
Autologous BMMSCs/BMAC
Soler et al., The
Knee (2016) [74] Knee K.L. 2/3 15 12 months -
Intra-articular

















in pain VAS and WOMAC
scores, aHAQ and
Lequesne index were seen
over time. No significant
changes were observed
regarding the social and
emotional roles and the

























of cartilage thickness at the
12-month follow up (MRI)
and significant
improvement of KOOS at




Knee K.L. 2–4 12 12 months -
Intra-articular
















of pain VAS and WOMAC
scores and Lequesne index
over time. No significant
changes in SF-36. MRI
revealed a significant
decrease in PCI at six and
12 months. A greater and
faster pain relief was noted
during sports performance.
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Table 2. Cont.




Arms and Mean Cell
Numbers
Outcome
















- No treatment-related SAEs
and AEs.
- Pain improvement was
maintained. Further significant
cartilage improvements were
seen in MRI (PCI) compared to







Knee K.L. 2/3 60 12 months Double-blinded
Intra-articular
injection of 2.5 × 107
cells (n = 10) vs.
5 × 107 cells (n = 10)
vs. 7.5 × 107 cells
(n = 10) vs. 15 × 107




followed by a 2 mL















A (n = 20)
- One treatment-related SAE
(synovial effusion) in the
150 × 106 cells group and nine
treatment-related AEs among
all cell-dose groups.
- A decrease of pain VAS score
and ICOAP in all treatment
groups, except for patients who
received 15 × 107 cells, over
time, yet without significance
when compared to placebo.
WOMAC score decreased in all
treatment groups, again
without significance. Although
not significant, the maximum
pain reduction in all scores was
observed in the low-dose





Knee K.L. ≥ 2 30 12 months Double-blinded
Intra-articular
injection of 4 × 107










injection of 3 mL
of HA (60 mg)
(n = 15)
- No SAEs and few mild
transient AEs, that affected
both groups.
- Significant pain reduction in
the treatment group at six- and
12-month follow-ups (pain VAS
score, WOMAC score,
Lequesne index). The active
control showed a significant
improvement in pain VAS score
only at the 12-month follow-up.
The treatment group showed
significant MRI improvements
at the 12-month follow-up.
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Knee K.L. ≥ 2 24 Six months Double-blinded
Intra-articular
injection of 108 cells









- MSC group with significant
improvement of WOMAC
score at six months; control
group without significant





Knee K.L. ≤ 3 44 24–25months Single-blinded
HTO and
intra-articular
injection of 4.11 × 106
cells (SVF) mixed
with











injection of 3 mL
of PRP (n = 23)
- Significantly greater
improvements in KOOS
sub-scales and pain VAS score
in the HTO + MSC + PRP
group compared to the HTO +
PRP group. Lysholm score was
significantly improved in both
groups at the final follow-up.
Second-look arthroscopy
findings after a mean of
19.8 months showed
significantly better cartilage






Knee K.L. 2/3 16 12 months Double-blinded
Arthroscopic
implantation
of SVF into one joint












mL of HA (n = 16)
- No SAEs, few local AEs that
resolved within two weeks.
- Pain and functional scores
improved significantly over
time in SVF-treated knees,
whereas HA-treated knees
worsened over time without
statistical significance.
Significantly improved
WORMS and MOCART scores
were also reported for






Knee K.L. 2/3 30 12 months -
Single intra-articular
injection of 108 cells
(n = 10) vs. repeated
(two) injections of 108
cells six months apart








treatment (n = 10)
- No SAEs, few self-limiting
mild and moderate AEs.
- Significant improvements for
both treatment groups in pain
and clinical outcomes over
time and compared to control.
No difference between
treatment groups. Cartilage
improvements or no further
cartilage loss in the repeated
injection group seen in MRI.
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Autologous ATMSCs









(n = 40) vs. HTO and
cells with allogenic









- Clinical outcomes improved
significantly for both groups at
second-look arthroscopy. From
the second-look arthroscopy to
the final follow-up only the
MSC allogenic cartilage group
improved. Kanamiya grading
was significantly higher in the
MSC group with allogenic
cartilage than in the MSC
group.





Knee K.L. 1/2 54 24–34months -
Arthroscopic
implantation of
3.9 × 106 cells (SVF)
without scaffold
(n = 37) vs.
arthroscopic
implantation of
3.9 × 106 cells (SVF)
mixed with fibrin glue









- Significant improvements of
IKDC score and Tegner activity
scale in both groups after a
mean of 12.3 months.
Significantly improved
arthroscopic ICRS grades in the
implantation + scaffold group
compared to the implantation
without scaffold group with a
significant correlation between
clinical outcomes and ICRS
grades.
Significant predictors for poor
clinical outcomes in the
implantation without scaffold
group were overweight (BMI >
25.5kg/m2) and large lesion
size (>5.7cm2). A similar trend
was observed in the
implantation + scaffold group,
yet without significance.





Knee K.L. 2/3 100 32 months -
HTO and
intra-articular
injection of a mean of
4.26 × 106 cells (SVF)








HTO (n = 50)
- Significant clinical
improvements in the HTO +
MSC group compared to the





to pre-operative findings, yet
they did not correlate with
clinical findings.
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injection of 1.89 × 106
cells, mixed with













injection of 3 mL
of PRP (n = 25)
- No SAEs, one patient experienced
marked knee pain with swelling,
following the injection which resolved
spontaneously. Few patients reported
slight knee pain in the first two or
three days after the injection.
- Significant improvements in pain
VAS score, Tegner activity scale and
Lysholm score at the final follow-up in
both groups. No significant differences
between the study and control group










injection of 4.1 × 106
















- Significant improvements in pain
VAS and AOFAS scores for both
groups at the final follow-up
compared to preoperative findings.
Clinical scores showed a significantly
greater improvement in osteotomy +
stimulation + injection group
compared to the control group.
ICRS grades correlated with clinical
findings and showed significantly
greater improvements in the
osteotomy + stimulation + injection
group compared to the control group
at the final follow-up. X-ray imaging
showed significant improvements in
both groups at the final follow-up
compared to preoperative findings
with no significant difference between
groups.





Knee K.L. 1/2 40 24–42months -
Arthroscopic injection
of 4.07 × 106 cells
(SVF) mixed with PRP
(n = 20) vs.
arthroscopic
implantation of
3.96 × 106 cells (SVF)
on a fibrin glue










- Significant improvements of IKDC
score and Tegner activity scale at the
final follow-up in the implantation
group with a significant difference
between groups. A significant
correlation between clinical outcomes
and ICRS grading (second-look
arthroscopy after a mean of 12.6
months) was seen, with significantly
greater improvements of ICRS grading
in the implantation group.
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- No SAEs, three AEs related to
harvesting procedure.
- Significant improvement of pain VAS
and IKS score over time. Patients with
a baseline pain VAS score > 8 showed
greater clinical and functional
improvements.





Knee K.L. 1/2 49 24–36months -
Arthroscopic
implantation of
4.3 × 106 cells (SVF)







- Significant improvements of IKDC
score and Tegner activity scale at the
final follow-up. A high prognostic
significance was observed regarding
age and lesion size. 60 years and a
lesion size of 6.0 cm2 were observed as
an optimum cut-off for poor clinical
outcomes.





Knee K.L. 1/2 35 24–34months -
Intra-articular








- Significant improvements of IKDC
score and Tegner activity scale at the
final follow-up.
Overweight patients (BMI >27.5
kg/m2) and patients with a large lesion
size (>5.4 cm2) had a significantly
worse outcome regarding IKDC score,
Tegner activity scale and ICRS grade.
Both, the Tegner activity scale and the
IKDC score were negatively correlated
with ICRS grades. Second-look
arthroscopic surgery revealed healed
chondral lesions after a mean of 12.7
months.





Knee K.L. 2/3 30 24–26months -
Intra-articular
injection of 4.04 × 106
cells (SVF) mixed












- No major complications, three
patients complained of slight knee
pain.
- Significantly improved clinical scores
at the 24-month follow-up compared
to the 12-month follow-up.
Second-look arthroscopy revealed
18.7% very positive, 43.8% positive,
25% neutral and 12.5% negative
cartilage healing results. Age and
mean improvement in KOOS
sub-scales were associated. K.L. grade
2 was associated with a higher
Lysholm score improvement.
J. Clin. Med. 2020, 9, 2062 18 of 35
Table 2. Cont.




Arms and Mean Cell
Numbers
Outcome






Knee K.L. 1/2 20 24 months -
Arthroscopic
implantation of
4.4 × 106 cells (SVF)











- Significant improvement of IKDC
score and Tegner activity scale at the
final follow-up. Significant
improvements in MRI scores with a
correlation between clinical and MRI





Knee K.L. 1–3 20 18 months -
Arthroscopic











- No SAEs and few self-limiting AEs,
two patients underwent arthroplasty
before trial completion.
- Significant pain VAS and WOMAC
score improvements at all follow-ups.
No MRI changes. Histological sections
of MSC-treated knees (who underwent








Knee - 19 12 months -
Intra-articular









- No complications reported.
- Significantly improved WOMAC
score at the six- and 12-month





Knee K.L. 3/4 18 24–26months -
Intra-articular
injection of 1.18 × 106










- Significant reduced WOMAC score
and improved Lysholm and pain VAS
score wat the final follow-up. MRI
score showed a significant





Knee K.L. ≥ 2 18 22 months -
Intra-articular
injection of 1 × 107
cells (n = 6) vs.
2 × 107 cells (n = 6) vs.
5 × 107cells (n = 6)
into each knee-joint,
followed by a third











- No SAEs and few AEs occurred
equally distributed among groups.
- WOMAC score and the NRS-11
significantly improved over time.
SF-36 showed a significant reduction
only at the three-month follow-up for
the low-dose group and at the
22-month follow-up for the
middle-dose group. MRI showed a
significant increase in cartilage volume
over time, compared to baseline.
The high-dose group showed the
greatest improvements overall.
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Autologous ATMSCs
Jo et al., Stem
Cells (2014) [99] Knee K.L. ≥ 2 18 Six months -
Intra-articular
injections of 1 × 107
cells (n = 3) vs.
5 × 107 cells (n = 3) vs.

















- No treatment-related SAEs or AEs.
- An improvement of pain VAS and
WOMAC score at the six-month
follow-up in the high-dose group. KSS
improved significantly in the low- and
high-dose group. MRI (size of
cartilage defect) showed a significant
improvement in the high-dose group.
Second look arthroscopy revealed a
significant reduction o cartilage defects
and of the ICRS grade in the high-dose
group. Histology showed regeneration
of articular cartilage defects
(descriptive only).













Jo et al., Stem
Cells (2014) [99]
“
- No treatment-related SAEs or AEs.
- Improvement in WOMAC score, KSS,
KOOS and reduced knee pain for up to
24 months were seen for any dose.
Statistical significance was reached
mainly in the high-dose group.
Clinical outcomes (WOMAC score)
declined after 12 months in the low-
and mid-dose group, whereas a
plateau was observed in the high-dose
group until 24 months. Similar results
were obtained for MRI evaluations.




Knee K.L. 3/4 18 Six months -
Intra-articular
injection of 2 × 106
cells (SVF) (n = 6) vs.
10 × 106 cells (SVF)
(n = 6) vs. 50 × 106














- No treatment-related SAEs and five
potentially treatment-related AEs.
- Improvement in pain, function and
mobility were observed, regardless of
dose. Significantly improved pain
levels and function were detected only
in the low-dose group. No correlation
between clinical changes and MRI. All
but one patient refused a previously
scheduled total knee arthroplasty.
Histological findings varied in their
description. No statistically significant
differences between groups for SF-36.
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Outcome






Knee IKDC B & D nine 18 months -
Intra-articular
injection of









- No SAEs and few AEs, that resolved
within one week.
- Significant improvements between
baseline and 3-month follow-up and
further improvements between 3- and
6-month follow-up in all scores. Scores
remained improved at 12- and
18-month follow-up, without further
significant development.
A significant cartilage restoration
(MOCART score) was observed at the
final follow-up, compared to baseline.
X-ray imaging showed neither
improvement nor deterioration.
Allogeneic UCMSCs




Knee K.L. 1–3 26 12 months Triple-blinded
Repeated (two)
intra-articular
injections of 2 × 107
cells in 3 mL of saline
with 5% plasma six
months apart (n = 9)
vs. single injection of
2 × 107 cells (n = 9),
followed by 3 mL of
saline with 5% plasma














injection of 3 mL
of HA (n = 8)
- No SAEs, few transient AEs (acute
synovitis and local pain).
- Significant pain and functional
improvements over time for
MSC-treated patients compared to
control. The single injection group
stopped improving after month 9,
while the repeated injections group
continued improving until final the
follow-up. All patients in the repeated
injections group were found to be
responders, according to the
OMERACT-OARSI Responder Index
Criteria. No changes in SF-36 and MRI.










holes at two different
dosages:
1.15–1.25 × 107 cells
(n = 4) vs.
















- No treatment-related SAEs and one
treatment-related AE.
- Pain VAS and IKDC score improved
significantly over time and remained
improved without significant
deterioration at the seven-year
follow-up. MRI showed high
glycosaminoglycan contents in
regenerated cartilage (qualitative).
Hyaline-like cartilage was found at
lesion sites at the one-year arthroscopic
follow-up in two patients with
histological findings of regenerated
cartilage (descriptive only).
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Knee K.L. 2–4 20 Six months Double-blinded
Intra-articular
injection of 5–6 × 107
cells in 1mL











injection of 10 mL
of saline (n = 10)
- No SAEs and four self-limiting AEs.
- Significantly improved pain score and
range of motion in the MSC group at
week 8. Cartilage thickness improved
in the MSC group only.
AE = adverse event; ATMSC = adipose tissue-derived mesenchymal stromal cell; aHAQ = Algofunctional Health Assessment Questionnaire; AOFAS = American Orthopaedic Foot
and Ankle Society; BMAC = bone-marrow aspirate concentrates; BMMSC = bone-marrow-derived mesenchymal stromal cell; dGMERIC = delayed gadolinium-enhanced-magnet
resonance imaging of cartilage; EQOL = Emory Quality of Life; FAOS = Foot and Ankle Outcome Score; GC = Glucocorticoid; HA = hyaluronic acid; HHS = Harris Hip Score;
HSS-KS = Hospital for Special Surgery knee score; HTO = high tibial osteotomy; ICOAP = Intermittent and Constant Osteoarthritis Pain Score; ICRS = International Cartilage Research
Society; IKDC = International Knee Documentation Committee; IKS score = International Knee Society knee and function score; K.L. = Kellgren and Lawrence; KOOS = Knee injury
and Osteoarthritis Outcome Score; KSS = Knee Society Score; MOAKS = MRI Osteoarthritis Knee Score; MOCART = Magnetic Resonance Observation of Cartilage Repair Tissue;
MRI = magnetic resonance imaging; NRS-11 = numerical pain rating scale-11; OA = osteoarthritis; OAOS = Osteoarthritis Outcome Score; OMERACT-OARSI Responder Index
Criteria = Outcome Measures in Rheumatology Committee (OMERACT)-Osteoarthritis Research Society International (OARSI) Responder Index Criteria; PCI = phase contrast imaging;
PGA = Patient Global Assessment; PLMSCs = Placenta-derived mesenchymal stromal cells; PRP = platelet-rich plasma; SAE = serious adverse event; SAS = Short Arthritis Assessment
Scale; SF-36 = Quality of Life Short Form-36; SF-12 = Quality of Life Short Form-12; SVF = stromal vascular fraction; UCMSC = umbilical cord-derived mesenchymal stromal cell;
VAS = Visual Analogue Scale; WOMAC = Western Ontario and McMaster Universities OA Index; WORMS = Whole-Organ Magnetic Resonance Imaging Score. “ = follow up study.
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As of April 13th 2020, the search on clinicaltrials.gov yielded 96 results. 25 trials were currently
recruiting OA patients for MSC treatment (see Table 1) and two additional trials were currently
recruiting, but not addressing MSC treatment in OA directly (acetabular labrum, “synovial brushing”
study). 34 trials were already completed, 11 were not yet recruiting and 24 were either “withdrawn”,
“unknown”, “suspended”, “terminated” or “active, not recruiting”.
3. Study Designs and Route of Cell Delivery
A total number of 42 clinical studies including 1325 OA patients were evaluated regarding study
type, methods, techniques and outcome measures. The majority of studies focused on OA of the
knee [63,64,66–72,74–87,89–105], while two studies treated OA of the hip and ankle [73,88]. This may
be due to the fact that knee OA has a high prevalence amongst all forms of OA with an estimated
lifetime risk of symptomatic manifestation of 40% in men and 47% in women [106,107] and a rather
safe and well-described protocol for intra-articular knee-injections [108].
In this review we identified six randomized, double-blinded, placebo-controlled trials, including
one follow-up study [64–66,78,105,109], eight randomized controlled trials [67–69,79,81–83,103] and two
prospective, randomized cohort studies [70,84]. Most studies were however prospective uncontrolled
clinical trials, comparative matched pair analyses, retrospective comparative studies or retrospective
case series and an inter-study comparison was difficult due to the variance in study design.
Studies varied further regarding protocols for intra-articular MSC delivery route.
Local application was either achieved through simple intra-articular injections of MSCs mixed
with saline [64,66,99,103,104,110] or PRP [69,70,81,87,89,93,96,97]. Implantation of MSCs was further
supported by allogenic cartilage [84], or the use of fibrin glue scaffolds [85,91,94]. Park et al. used drill
holes [104] and other groups combined MSC applications with surgical correction operations like HTO
for knee OA [81,84,86] or lateral sliding calcaneal osteotomy for ankle OA [88].
4. Safety
Although not all of the included studies evaluated the safety of MSC-based treatment for OA,
all reported treatment-related serious adverse events (SAEs) and AEs were described to have subsided
without sequelae. Treatment-related AEs included either injection site complications like local knee
pain and swelling or harvesting site complications like low back pain after iliac bone harvesting and
haematoma after liposuction.
Gupta et al. reported one treatment-related SAE (synovial effusion) and nine treatment-related
AEs in a study of 60 patients with knee OA after intra-articular injections of allogenic BMMSCs.
No sequelae of the SAE were reported [78]. Bastos et al. reported two treatment-related SAEs (intense
knee pain) and eight treatment-related AEs in 18 knee OA patients, treated with autologous BMMSC
injections. SAEs were treated with analgesics and resolved without lasting impairments [70].
Mild to severe AEs were reported in 80–100% of patients receiving either single or repeated
ATMSC injections for knee OA in a trial by Freitag et al. No significant difference was observed
between treatment groups. Discomfort and swelling at the injection site were the most commonly
reported AEs [83].
Soler et al. reported of 14 mild and two moderate treatment-related AEs ranging from arthralgia
and joint swelling to knee locking and back pain in a study of 15 knee OA patients treated with
autologous BMMSC injections [74]. Orozco et al. reported transient and mild injection site pain for a
few days in 50% of patients in a study treating 12 knee OA patients with autologous BMMSCs [76].
Song et al. reported 20 treatment-related AEs in 18 patients, receiving different intra-articular cell
doses of autologous ATMSCs for OA of the knee. Transient pain and joint swelling occurred equally
distributed among groups and were all spontaneously relieved [98]. Chahal et al. treated 12 patients
with BMMSCs for knee OA and reported of four patients with minor transient AEs (local pain and
swelling), which all subsided without intervention [72].
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None of the authors reported any lasting impairments resulting from treatment-related SAEs or
AEs. All reported cases resolved within a few days and no patient had to terminate any of the trials
preliminary due to safety issues. Moreover, reported AEs were similar to those previously reported
during clinical trials, evaluating intra-articular injections of HA or GC [111,112]. It can therefore be
assumed that treatment-related AEs are of procedural nature and that intra-articular MSC injections
are safe, regardless of tissue origin and applied cell dose. Long-term follow up studies of seven and
four years, conducted by Park et al. [104] and Lamo-Espinosa et al. [15] reported no further SAEs and
AEs that persisted over the acute post-injection phase.
5. Duration of Therapeutic Effects
Preferably, an ideal treatment should improve symptoms for a long duration, halt disease
progression and ultimately heal the patient’s condition. Unfortunately, this is rarely the case and an
amelioration of symptoms for as long as possible is a more realistic goal for most therapies treating
degenerative joint diseases. Taking a look at scheduled follow-ups of included studies, most studies
followed-up on their patients for six to 24 months [64,66–72,74–80,82,83,87,90,94–96,98–103,105].
Almost all included studies recorded clinical improvements and cartilage regeneration for the first
12 months after the treatment. Studies with longer follow-up periods reported further improvements
over time [85,86,88–90,95], plateau phases with maintained clinical improvements [100,104],
or deterioration of previous improvements after 30 months [73]. A four-year follow-up study, conducted
by Lamo-Espinosa et al., showed clinical and functional improvements four years after a single
intra-articular injection of BMMSCs [65]. Larger randomized controlled trials with extended follow-up
visits will be needed to gain further insights into the question of how long locally injected MSCs can
exert their effects on the joint. So far, relevant clinical improvements have been recorded for as long as
six to 12 months in most published studies.
6. Quality of Life and Mental Health
The Quality of Life Short Form-36 (SF-36) questionnaire evaluates quality of life, using eight
sub-scores, concerned with the physical and mental status of the patient. It is widely used to evaluate
therapy success with a focus on the patient’s physical and emotional state during or after an intervention.
Interestingly, while most evaluated clinical (e.g., pain visual analogue scale (VAS) score) and structural
(e.g., Whole-Organ Magnetic Resonance Imaging Score (WORMS)) parameters of included studies
improved over time, results of the SF-36 did often not correlate [74,76,101,103]. The SF-36 questionnaire
is often criticized for being too generic and less sensitive than for example the Western Ontario and
McMaster Universities OA Index (WOMAC) score, which was specifically developed to assess lower
extremity arthritis [113]. The SF-36 questionnaire should therefore be interpreted with caution and
may be replaced if possible, by more specific alternatives.
7. Radiological and Arthroscopic Outcome Evaluations
To quantify newly-formed cartilage following MSC-based therapies, MRI studies [67,72,74,79,80,
82,83,97,103,105,114] or second-look arthroscopy interventions [81,84–86,88,89,92,93,99,100,104] can
be performed to analyse structural improvements through MSC-based treatment.
MSC-induced cartilage improvements, visible in MRI, are an ongoing topic of debate and
contradicting results are continuously reported. While some authors demonstrate cartilage regeneration
in accordance with clinical improvements [76,77,82,87,97,99], others could not confirm changes in
cartilage structure, although clinical improvements were observed [95,103,115].
In 2008 Centeno et al. reported one of the first intra-articular injections of autologous BMMSCs
in a patient with OA of the knee. The group found that six months after treatment the patient had
already shown statistically significant growth of cartilage and meniscus in the conducted MRI [114].
Soler et al. and Vega et al. could both confirm improved cartilage quality at the 12-month follow-up
for knee OA patients, treated with BMMSCs [74,79]. Wong et al. showed a significantly improved
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Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score one year after HTO,
microfracturing and intra-articular injection of autologous BMMSCs mixed with HA in 28 knee OA
patients compared to the control group, comprised of 28 OA patients who underwent the same
procedure without MSC injection [67]. In 2013, Koh et al. reported that improved MRI scores were
positively correlated with the number of injected MSCs [97].
Pintal et al. treated 19 knee OA patients with autologous ATMSCs and although they observed a
significant improvement in clinical scores at the six- and 12-month follow-up, no significant differences
in cartilage constitution were observed in the conduced MRI [96]. Gupta et al. treated 60 knee OA
patients with varying doses of allogenic BMMSCs against a control group. While pain VAS and clinical
scores improved in all treatment groups, no cartilage changes were detected [78]. In accordance,
Matas et al. found significant pain and functional improvements in knee OA patients, treated with
UCMSCs, yet no structural changes were evident in conducted MRI [103].
As an alternative more invasive outcome measure, arthroscopic evaluations can be conducted,
which are mostly performed as a second-look intervention at a scheduled follow-up.
In 2018 Kim and Koh performed a comparative matched-pair analysis, comparing outcomes of
HTO-treated with HTO + SVF-treated knee OA patients. The authors reported significant cartilage
improvements in the latter, according to ICRS grades, assessed 12 months after the intervention. ICRS
grades correlated further with clinical outcome measures [86].
Koh et al. compared HTO + PRP + autologous ATMSC-treated (n = 21) with HTO + PRP-treated
knee OA patients (n = 23) and second-look arthroscopy after a mean of 19.8 months showed significantly
more cartilage healing in the HTO + PRP + ATMSC group [81]. According to the Kanamiya grading
system [116], 50% of patients in the HTO + PRP + MSC group showed partial or fibrocartilage cover,
whereas this was only shown for 10% in the control group [81].
Most of the aforementioned studies need to be interpreted with caution as they showed a low
level of evidence. Results from a recent meta-analysis that assessed five randomized controlled trials
on MSC-based therapy for knee OA [64,67,78,79,81] found that limited evidence for pain relief and
functional outcomes does exist, yet there is a lack of evidence to support the claim that MSC-based
therapy facilitates cartilage repair [115].
8. Cell Dose
The evaluation of cell dosing is important in order to find the minimum dose of MSCs, which is
safe and still provides best overall outcomes. Given the limited amount of data and protocols on MSC
therapy, most of the included studies were in fact dose-finding phase I or II trials.
The used cell doses ranged from the lowest mean dose of 1 × 106 autologous BMMSCs [72] to
a mean dose of 1.5 × 108 allogenic BMMSCs [78]. The lowest mean dose was used by Chahal et al.
in a dose-finding trial from 2019. Twelve knee OA patients were treated with escalating cell doses.
Best clinical and radiological results were obtained in the high dose group of 5 × 107 cells [72].
Gupta et al. compared four doses of allogenic BMMSCs (2.5 × 107, 5 × 107, 7.5 × 107 and 1.5 × 108
BMMSCs mixed with 2 or 4 mL of PLASMA-LYTE A followed by an injection of HA (20 mg) in 60 knee
OA patients in a randomized, double-blinded, multicentric, placebo-controlled study. They were able
to show that the lowest dose of 2.5 × 107 cells provided the maximum pain reduction in all subjective
parameters (WOMAC and pain VAS score), yet the observed improvement was not significant, when
compared to placebo [78].
Pers et al. compared three cell doses (2 × 106, 1 × 107 and 5 × 107 autologous ATMSCs in the form
of SVF) and showed that patients treated with the lowest dose experienced significant improvements in
pain and function WOMAC sub-scores, compared to baseline values. Of note, patients in the low-dose
group had higher pain and function WOMAC sub-scores at baseline, compared to those receiving
higher doses, which may have put a bias on the reported results [101].
In contrast, other authors yielded the best results for much higher cell doses in their
studies [64,99,100,114]. Jo et al. compared three doses of autologous ATMSCs (1 × 107, 5 × 107
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and 1 × 108 ATMSCs) for the treatment of 18 knee OA patients. Improvements in the WOMAC
score and improved cartilage volumes in MRI were observed in the high-dose group after six months.
Second-look arthroscopy revealed a significant reduction of cartilage defects and a reduction of the
International Cartilage Research Society (ICRS) grade in the high-dose group [99].
Jo et al. continued evaluating patients in a second phase of the study for a two-year follow-up.
Improvements in WOMAC score, the Knee Society Score (KSS), the Knee injury and Osteoarthritis
Outcome Score (KOOS) and reduced knee pain for up to 24 months were observed in both, the low-
and the high-dose group. However, statistical significance was reached mainly in the high-dose group.
Clinical outcomes and MRI scores declined after 12 months in the low- and mid-dose group, whereas a
plateau was observed in the high-dose group until the 24-month follow-up [100]. A 2019 study by
Freitag et al. found no differences between patients who were treated with a single injection of 1 × 108
cells or those who were treated with repeated injections of the same dose, six months apart (each time
1 × 108 cells) [83].
A retrospective analysis of 373 patients, who received autologous BMAC and PRP for
424 osteoarthritic knee joints, was able to demonstrate that patients receiving > 4 × 108 cells
showed significantly lower post-treatment numeric pain scale values than patients receiving
<4 × 108 cells. However, improved function according to the Lower Extremity Functional Scale and the
International Knee Documentation Committee (IKDC) score were seen in all patients, regardless of
dose. The preference of the relatively high cell dose in this study was biased by the cell count, which
included all nucleated cells in the BMAC (BMMSCs, haematopoietic stem cells, monocyte precursor
cells, macrophages, B- and T-cells, etc.) and not only MSCs [117].
The analysis of the existing data underlines that only limited evidence exists on the most efficient
cell dose in OA treatment to date. The range of the ideal therapeutic doses is still open for debate and
discussed vividly among physicians and scientists. Yet, data shows that a dose range from a mean of
1 × 106 autologous BMMSCs [72] to a mean of 1.5 × 108 allogenic BMMSCs [78] appears to be safe and
effective in selected parameters.
Finally, a meta-analysis by Kim et. al. could not find a recommended cell dose, due to a great
variation of concentrations, applied in different randomized controlled trials [115].
Further dose-finding, randomized, controlled, blinded and preferably matched trials with larger
numbers of participants are needed in order to avoid biased results.
9. Tissue Origin
The majority of trials covered by this review used autologous ATMSCs for OA treatment.
Twelve studies used ATMSCs in the form of SVF [81,82,85,86,88–91,93,94,96,101], ten studies used
pure-expanded autologous ATMSCs (including one follow-up study) [80,83,84,87,92,97–100,102] and
one study used concentrated adipose tissue [95]. Fourteen studies used autologous BMMSCs
(including two follow-up studies) [64–76], two used allogenic BMMSCs [78,79], two allogenic
umbilical cord-derived MSCs (UCMSCs) [103,104] and one study used allogenic placenta-derived
MSCs (PLMSCs) [105].
ATMSCs can easily be harvested through a simple and minimally invasive liposuction procedure.
Liposuctions can be performed repeatedly and harvested cells show rapid expansion potential when
cultured [118]. Adipose tissue contains a substantially higher number of MSCs than bone-marrow
and ATMSCs are less affected by age and morbidity of patients. Further, ATMSCs maintain
their differentiation potential even at later stages of life [119]. ATMSCs also exhibit the strongest
anti-inflammatory potential when compared with other MSC sources [120].
Numerous clinical studies have proven the safety and efficacy of SVF therapy for OA. The isolation
process and injection can usually be performed during the same visit, which makes SVF treatment
an attractive alternative to pure ATMSC injections. Despite these advantages, the use of autologous
ATMSCs has limitations. Cell manipulation due to ex vivo preparation and a lack of standardized
harvesting protocols may impact the quality and quantity of cells. In this context, the MSC secretome,
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a valuable source of EVs, growth factors, and cytokines, has emerged as a possible cell-free therapeutic
alternative [121]. Tofiño-Vian et al. were able to show that ATMSCs could serve as a source for EV
exploitation [122], yet OA treatment, using the isolated secretome, has so far only been conducted in
pre-clinical studies [121,123].
Currently recruiting clinical trials (see Figure 1) show a growing trend towards the use of
allogenic UCMSCs and Wharton Jelly-derived MSCs (WJMSCs). Park et al. used UCMSCs in the
treatment of seven knee OA patients and performed an extended follow-up of seven years. The study
reported improved cartilage tissue at the 12-week follow-up and significantly improved pain VAS and
IKDC scores at the 24-week follow-up. Improved clinical scores remained stable without significant
deterioration for up to seven years. MRI findings showed preserved regenerated cartilage after
three years [104]. A recently published study supports the favourable safety and efficacy profile of
UCMSCs for knee OA treatment in 23 patients [103]. PLMSCs were also reported to be safe and
effective regarding pain relief and improved range of motion in OA patients. Significant changes in the
PLMSC-treated group were however only detected until eight weeks after treatment, when compared
to the saline-treated control group [105]. Further studies with bigger patient samples are required to
assess the safety and efficacy of UCMSCs and PLMSCs in depth.
Direct comparisons of MSCs from different tissue origins are scarce, yet Mautner et al. compared
the efficacy of BMAC with that of microfragmented adipose tissue for the treatment of knee OA.
Both autologous treatments significantly improved pain and function scores over time, yet no significant
difference was seen between the two groups [71]. Vega et al. conducted a direct efficacy comparison
between their own study from 2015 [79] using allogenic BMMSCs and a study by Orozco et al. from
2013 [76] using autologous BMMSCs and a study by Jo et al. from 2014 [99] using autologous ATMSCs
for the treatment of knee OA.
For the inter-study comparison, the group evaluated the efficacy by taking pain relief divided by
the initial pain score, a method described by Huskisson et al. in 1974 to provide a tool for assessing
general treatment efficacy [124]. The results showed the best efficacy of 0.75 for the autologous BMMSC
treatment (Orozco et al. [76]) with an effect size of 1.29 versus an efficacy of 0.39 and an effect size
of 0.96 for the autologous ATMSC treatment (Jo et al. [99]). A slightly worse efficacy of 0.36 was
determined for the allogenic BMMSC treatment with an effect size of 1.07 (Vega et al. [79]).
Due to the differing patient numbers, control arms, follow-ups and injection protocols of MSC
injections, a comparison of studies like this has limited relevance. This was also concluded by
Shariatzadeh et al. in a recent review comparing the level of efficiency of different MSC sources for knee
OA treatment. The authors concluded that exact protocols of MSC characteristics, culture, dosage, and
clinical application are necessary for a final evaluation and efficient comparison of different studies [39].
Vega at al. suggested future studies that directly compare autologous and allogenic MSCs within
the same study [79]. Applying similar treatment protocols to both study arms would help to determine
the most suitable source of MSCs, and analogous to dose-finding trials, “source-finding trials” would
improve knowledge on safety and efficacy of different MSC tissue origins.
10. Independent Outcome Predictors
Identifying factors that are directly associated with clinical outcomes of a treatment is valuable
as it allows prognostic statements about the efficacy of a potential therapy. Schiavone Panni et al.
could recently demonstrate that patients with a baseline pain VAS score > 8 showed significantly
greater improvements in clinical and functional outcomes after SVF-based treatment, when compared
to patients with pain VAS scores < 8 [90].
Koh et al. observed that overweight patients (BMI > 27.5 kg/m2) and patients with a large cartilage
lesion size (≥5.4 cm2) showed significantly worse clinical (IKDC score and Tegner activity scale) and
arthroscopic (ICRS grade) outcomes in ATMSC-treated knee OA patients. Other factors, including
age and sex, did not have a significant influence on outcomes [92]. The negative effect of morbid
obesity on ATMSCs’ proliferation potential and multilineage differentiation capacity was proven in
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previous animal and human studies and may be linked to the high secretion of inflammatory cytokines
in overweight patients [125,126].
Kim et al. [91] confirmed these findings in a retrospective study from 2015, analysing 49 knee OA
patients after intra-articular autologous ATMSC treatment. The group could show that patient age and
cartilage lesion size were independent predictors of clinical failure. Patients older than 60 years and
patients with cartilage lesions larger than 6.0 cm2 were at risk of poor clinical outcomes (IKDC score
and Tegner activity scale). The study also showed a statistically significant association between age
and cartilage lesion size as well as between BMI and cartilage lesion size. Sex, side of involvement (left
or right), lesion location and BMI could not predict clinical outcomes independently [91].
These findings were contradicted by a 2016 study from the same group, treating 20 knee OA
patients with an arthroscopic autologous ATMSC implantation. The study concluded that sex, BMI,
size and location of the cartilage lesion were no independent risk factors for poor clinical outcomes [94].
Soler et al. described patients younger than 65 years with mild to moderate OA of the knee as
the ideal candidates for intra-articular MSC application. In their trial from 2016, the group treated 15
patients with a mean age of 52 years with autologous BMMSCs and showed significant improvements
in clinical scores and cartilage repair (MRI) after 12 months [74].
Koh et al. examined 30 knee OA patients, older than 65 years of age, who received intra-articular
autologous ATMSC injections in 2015. Almost all patients showed significant improvements in KOOS,
pain VAS and Lysholm scores at the final two-year follow-up. Cartilage status improved or was
maintained in 87.5% of the patients two years after treatment and none of the patients underwent
total knee arthroplasty during the two-year follow-up period [93]. These findings question the cut
off for intra-articular MSC therapy at the age of 60, suggested by Kim at al. [91]. Finally, Chahal et al.
showed that anti-inflammatory markers, assessed from autologous BMMSCs after harvesting, were
strongly predictive of clinical outcomes, including WOMAC and KOOS scores [72]. This points towards
potential valuable screening panels, that may be applied in the future. Such panels could help identify
patients, who would benefit most from MSC-based treatment, and those who would not.
11. Conclusions and Outlook
MSC therapies have been successfully realized in a limited number of clinical trials, treating
patients with OA. First impressions show that locally applied MSCs seem to halt disease progression,
partially regenerate cartilage and alleviate pain. Yet, the existing clinical studies vary strongly in
treatment protocols, levels of evidence and follow-up periods. Interpretation of these data demands
a differentiated view and more scientific engagement is undoubtedly required to provide further
evidence for the specific efficacy of MSC treatment in OA. Thus, we suggest keeping a substantial
critical view on these innovative new therapeutics and propose to establish standards in documentation,
clinical trial management and handling to ensure comparability across trials.
The vast majority of MSC studies for OA target the knee joint, most likely due to the high
prevalence amongst all forms of OA. Yet, results from included studies do not allow a direct translation
to other joints. Shoulder and hip joints for example have different biomechanics compared to the knee
joint and therefore have to be analysed from that view. Whereas we are hoping for more randomized,
double-blinded, multicentric, placebo-controlled phase III trials in knee OA, there is also a big need for
phase I and II studies, examining other forms of OA.
According to the trials included in this review, MSC treatment for knee OA has shown only a
few adverse effects, which were all likely due to the procedural nature of intra-articular injections and
MSC harvesting procedures. However, the majority of safety studies provided only a short follow-up
period or a limited sample size, and thus final safety conclusions remain difficult. Results indicate
some efficacy in selected parameters over a duration of at least several months. The biggest drawback
of the current clinical evidence for MSC-based therapy is that most of the included studies did not have
resilient control groups, which reduces the level of evidence and makes results less reliable. Therefore,
a detailed analysis and comparison of the costs and therapeutic alternatives for the daily clinical
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practice seem necessary. Most clinical trials include patients with mild to moderate OA, where MSCs
are believed to work best by targeting the persisting low-grade inflammation. Patients with more severe
OA proved not to be the ideal candidates for MSC-based treatments, as osteophytes, subchondral
sclerosis and cysts are unlikely to be altered by MSCs. Therefore, MSCs cannot be understood as an
alternative to arthroplasty surgery, but potentially as an additional therapy for early onset and mild to
moderate cases of OA.
Although the mechanisms by which MSCs exert their effects on affected joints are not fully
understood, it is generally accepted that immunomodulatory and anti-inflammatory properties on the
one hand and repair and restoration mechanisms on the other hand, have a synergistic or additive effect
on the osteoarthritic joint. Future research should put a critical focus on the emerging role and potential
clinical application of the MSC secretome and its biologically active factors. The enhancement and
modulation of MSCs’ paracrine effects by priming may further increase their capacities to adequately
alleviate pain and potentially restore joint integrity and function in OA-troubled patients.
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